Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.50 |
| ▸ | CTSD | P07339 | 5/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136308 | 0.91 | AR (0.47) | ARPGRCTSK | |
| SCHEMBL4132840 | 0.88 | ANPEP (0.48) | ARPGRCTSKATM | |
| SCHEMBL4133321 | 0.87 | ERCC1 (0.46) | ARPLA2G7 | |
| SCHEMBL4136219 | 0.86 | PLA2G7 (0.42) | ARPLA2G7 | |
| SCHEMBL4135308 | 0.86 | AR (0.45) | ARPGRCTSK | |
| SCHEMBL4141038 | 0.86 | AR (0.45) | ARPGRCTSK | |
| SCHEMBL4135589 | 0.86 | NR3C1 (0.44) | ARPGRCTSK | |
| SCHEMBL4135669 | 0.86 | AR (0.51) | ARPGRCTSK | |
| SCHEMBL4136182 | 0.85 | AR (0.50) | AR | |
| SCHEMBL13771896 | 0.84 | AR (0.44) | ARPLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192202-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-30 | — | — | US | disclosed |
| US-7507860-B2 | Androgen modulators | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070197641-A1 | Androgen modulators | HU LAIN-YEN | 2007-08-23 | — | — | US | disclosed |
| EP-1737813-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100305-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197641-A1 | Androgen modulators | AR, NR5A1, SHBG | AR 1/4885CTSD 2987/4885PGR 43/4885 |
| US-20090192202-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885CTSD 2987/4885PGR 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.